618 filings
Page 8 of 31
8-K
vuc 6ib90zf3vk
27 Apr 21
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
9:31am
DEFA14A
igx2a baov749p
26 Apr 21
Additional proxy soliciting materials
9:00am
8-K
ik0fe2k3ccy49ytzed7
26 Apr 21
VBI Vaccines Announces Presentation at the 2021 Annual Conference on About Hepatitis B
8:00am
8-K
z08vvtts8ozx64daoj
21 Apr 21
Regulation FD Disclosure
8:00am
8-K
fgto9um2
12 Apr 21
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
8:00am
8-K
h3tr 6oz6i
15 Mar 21
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
8:00am
8-K
sok6ic7e 80zx7rwvsu
10 Mar 21
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
7:38am
8-K
epdf2smitrg1d9hl
2 Mar 21
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021
8:00am
8-K
iwfl pyzy6
1 Mar 21
VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference
8:00am
8-K
20a61
2 Feb 21
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
8:21am
8-K
fqng6njer 9bsa
21 Jan 21
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
9:25am
8-K
pq2qw8zqi8w
15 Jan 21
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s
8:24am
8-K
56pvz3
23 Dec 20
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing
11:21am
8-K
evu7nusr c63b73pr8
7 Dec 20
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
10:23am
8-K
n0soc
2 Dec 20
Regulation FD Disclosure
8:57am
8-K
aqcmbge 1a2
1 Dec 20
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
8:16am
8-K
pfqvbk8h v2kuqaq
23 Nov 20
Other Events
1:20pm
8-K
1qo49cvcmztn d773
19 Nov 20
Regulation FD Disclosure
8:00am